Introduction
============

Acute promyelocytic leukemia (APL) is a distinct clinical and pathologic entity associated with fusion of the promyelocytic leukemia (*PML*) gene with the retinoic acid receptor α (*RARA*) gene (*PML--RARA*), formed by the t(15;17)(q22;q21) chromosomal translocation.[@b1-ott-10-2305] The use of differentiation induction therapy with all-trans retinoic acid (ATRA) has significantly improved the prognosis of APL. The combination of ATRA and anthracycline-based chemotherapy that is currently considered the standard of care for newly diagnosed APL[@b2-ott-10-2305] yields complete remission (CR) rates of approximately 80%--95% and long-term disease-free survival (DFS) rates exceeding 80%.[@b3-ott-10-2305],[@b4-ott-10-2305] Therefore, much focus has been placed on the prevention of relapse for APL patients in CR.

In addition to ATRA, arsenic trioxide (As~2~O~3~) has been shown to induce sustained molecular remission in APL patients who relapse after treatment with ATRA-containing regimens.[@b5-ott-10-2305]--[@b7-ott-10-2305] Of greater relevance, several studies have shown that the early addition of As~2~O~3~ to induction and/or consolidation regimens might provide another approach to improve the outcome of APL.[@b8-ott-10-2305]--[@b12-ott-10-2305] However, for APL patients who have achieved CR after completing consolidation therapy, the role of maintenance therapy remains a matter of discussion, especially for the low- to intermediate-risk category. Maintenance with different combinations of ATRA, chemotherapy, and As~2~O~3~ has been used over different time periods. Two previous randomized studies reported the benefit of maintenance therapy with ATRA and/or low-dose chemotherapy (6-mercaptopurine \[6-MP\] and methotrexate \[MTX\]),[@b13-ott-10-2305],[@b14-ott-10-2305] and this was later confirmed by the analysis of long-term outcomes.[@b15-ott-10-2305],[@b16-ott-10-2305] However, the Italian GIMEMA group demonstrated no significant benefits in 12-year DFS in patients administered maintenance therapy with any of those three options (6-MP plus MTX, ATRA, and both), compared with observation in APL patients achieving molecular CR by the AIDA 0493 protocol (ATRA plus idarubicin \[IDA\]).[@b17-ott-10-2305] Thus, for patients achieving molecular CR after intensive induction and consolidation therapy, the benefit of maintenance therapy has been questioned. Until recently, a meta-analysis conducted by Muchtar et al that included nine randomized controlled trials suggested that maintenance therapy improves DFS. As for the type of maintenance regimen, ATRA and chemotherapy compared with ATRA alone improves DFS.[@b18-ott-10-2305] However, incorporation of As~2~O~3~ into an effective therapeutic arsenal against APL further confounds the effects of maintenance therapy. The results of several of the latest trials have demonstrated the efficacy and safety of ATRA plus As~2~O~3~-based maintenance therapy in newly diagnosed APL patients.[@b19-ott-10-2305],[@b20-ott-10-2305] Furthermore, to our knowledge, the comparative efficacy of the ATRA plus As~2~O~3~ maintenance strategy with classic ATRA plus chemotherapy has not been evaluated.

In this study, a retrospective analysis was conducted to compare the efficacy and toxicity of maintenance therapy with ATRA plus As~2~O~3~ and classic ATRA plus chemotherapy in low- to intermediate-risk APL patients reaching the first CR (CR1) after induction and consolidation therapy.

Patients and methods
====================

Population and study design
---------------------------

APL was initially diagnosed based on morphology and immunophenotyping, and confirmed genetically by the presence of the *PML--RARA* fusion gene and/or the t(15;17) chromosomal translocation. Eligible patients included adults (≥15 years) with newly diagnosed APL, classified as low- to intermediate-risk category (white blood cell \[WBC\] count at diagnosis ≤10×10^9^/L). The treatment strategies employed are shown in [Figure 1](#f1-ott-10-2305){ref-type="fig"}. Remission induction therapy consisted of oral ATRA (25 mg/m^2^/day \[day 1 until CR\]) plus IDA (10--12 mg/m^2^/day \[days 2, 4, and 6\]) with or without intravenous As~2~O~3~ (0.16 mg/kg/day \[days 1--28\]). This was followed by four cycles of consolidation. Each cycle included the ATRA plus IDA or mitoxantrone (Mitox) regimen (ATRA: 25 mg/m^2^/day \[days 1--14\] and IDA: 10--12 mg/m^2^/day \[days 1--3\], or Mitox: 6 mg/m^2^/day \[days 1--3\]). During induction and consolidation therapy, IDA dosage was decided based upon the patient's age: 12 mg/m^2^/day for patients aged 15--60 years; 10 mg/m^2^/day for those aged 61--70 years. To avoid central nervous system (CNS) relapse, all patients received at least three intrathecal injections of three drugs containing MTX (10 mg), dexamethasone (5 mg), and cytarabine (50 mg) during consolidation therapy.

From February 2008 to November 2014, all adult patients with newly diagnosed APL reaching CR1 after induction and consolidation received 2 years of maintenance therapy with either the ATRA plus As~2~O~3~ regimen (ATRA \[25 mg/m^2^/day\] for 14 days, As~2~O~3~ \[0.16 mg/kg/day\] for 14 days, and sequential use of the two agents with an interval of 14 days), or eight 3-monthly cycles of the ATRA plus chemotherapy regimen (ATRA \[25 mg/m^2^/day\] for 14 days of each cycle, alternating with 6-MP \[50 mg/m^2^/day\] and MTX \[10--15 mg/m^2^/week\] for the remainder of each cycle). This retrospective study was reviewed and approved by the Institutional Review Board (IRB) at the First Affiliated Hospital of Wenzhou Medical University. The requirement for informed consent was waived by the IRB due to the retrospective nature of this study, but patient confidentiality was protected.

Molecular monitoring
--------------------

Regular real-time quantitative polymerase chain reaction assays for the *PML--RARA* fusion transcript were performed on the bone marrow sample obtained at diagnosis, after induction and each consolidation cycle, and subsequently, every 3 months for 3 years. Molecular relapse was defined as the reappearance of *PML--RARA* positivity after achievement of molecular remission at the end of consolidation that could be verified in a subsequent consecutive sample taken 2 weeks later. Frank relapses were confirmed by morphological and molecular analyses.

Statistical analysis
--------------------

All data were censored on November 1, 2016. Relapse-free survival (RFS) was measured from the completion of consolidation until relapse of any kind. The probability of RFS was calculated using the Kaplan--Meier method. Differences in RFS were tested using log-rank analysis. Categorical variables were compared using the Fisher's exact test or chi-square test. Numerical variables were compared using the Wilcoxon rank-sum test. A two-tailed *P*-value of \<0.05 was considered statistically significant. All statistical analyses were performed using the Stata version 12 software (StataCorp LP, College Station, TX, USA).

Results
=======

Patient characteristics
-----------------------

In total, 58 eligible patients reaching CR1 after induction and consolidation therapy received maintenance therapy with either ATRA plus As~2~O~3~ (ATRA+As~2~O~3~ group, N=30) or ATRA plus chemotherapy containing 6-MP and MTX (ATRA+chemotherapy group, N=28). The median age of the participants was 41 years (range: 15--70 years), and six were older than 60 years. Characteristics of the 58 patients according to the type of maintenance regimen are presented in [Table 1](#t1-ott-10-2305){ref-type="table"}. Significant differences were noted between the two maintenance groups in terms of sex and WBC count at diagnosis. The percentage of male patients in the ATRA+chemotherapy group (67.9%) was significantly higher than that in the ATRA+As~2~O~3~ group (40.0%) (*P*=0.034), while the percentage of patients with a WBC count at diagnosis \<5×10^9^/L was significantly lower in the ATRA+chemotherapy group (71.4%) than in the ATRA+As~2~O~3~ group (93.3%) (*P*=0.027).

Adverse events observed during maintenance
------------------------------------------

All 58 patients receiving maintenance therapy were reviewed, to evaluate the incidence of toxicity during maintenance (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03).[@b21-ott-10-2305] A total of 24 adverse events (seven in the ATRA+As~2~O~3~ group vs 17 in the ATRA+chemotherapy group) were reported in 23 patients (seven in the ATRA+As~2~O~3~ group vs 16 in the ATRA+chemotherapy group) ([Table 2](#t2-ott-10-2305){ref-type="table"}).

### Hematologic toxicity

Grade 3--4 neutropenia was significantly more frequent in the ATRA+chemotherapy group (N=9, 32.1%) than in the ATRA+As~2~O~3~ group (N=0) (*P*=0.001). Grade 3--4 thrombocytopenia was not observed in either group during maintenance.

### Nonhematologic toxicity

Three out of 30 patients (10.0%) in the ATRA+As~2~O~3~ group and four out of 28 patients (14.3%) in the ATRA+chemotherapy group had reversible liver function derangements during maintenance (*P*=0.701). Prolongation of the QT interval, defined as a corrected QT interval ≥450 ms in men and ≥460 ms in women calculated using the Framingham formula,[@b22-ott-10-2305] was observed in two patients (6.7%) in the ATRA+As~2~O~3~ group, and was not observed in the ATRA+chemotherapy group (*P*=0.492). There were no reports of life-threatening cardiac arrhythmias. Dyspepsia was reported in one patient (3.3%) in the ATRA+As~2~O~3~ group and in three patients (10.7%) in the ATRA+chemotherapy group (*P*=0.344). Two out of 58 patients experienced other adverse events, including herpes zoster reactivation (one in the ATRA+chemotherapy group) and hemolysis (one in the ATRA+As~2~O~3~ group). All clinical signs improved after symptomatic treatment only or observation, with the exception of hemolysis that was resolved with temporary discontinuation of As~2~O~3~ and symptomatic treatment.

Relapse and survival
--------------------

At a median follow-up of 49.1 months (range: 9.7--97.4 months) from the completion of consolidation, no relapses were observed in the ATRA+As~2~O~3~ group, whereas seven relapses were observed in the ATRA+chemotherapy group. Of the seven relapsed patients, five presented with frank relapse (bone marrow, N=4; CNS, N=1), and two presented with molecular relapse. Death occurred in one patient, 8.8 months after relapse. The other six patients who relapsed received salvage therapy with As~2~O~3~, and all achieved molecular CR and remained alive at the final follow-up.

To define the risk of relapse in patients during maintenance, the impacts of sex, age (≤40 years vs \>40 years), WBC count at diagnosis (≤5×10^9^/L vs \>5×10^9^/L), platelet count at diagnosis (≤40×10^9^/L vs \>40×10^9^/L), hemoglobin level at diagnosis (\<100 g/L vs ≥100 g/L), and types of induction regimen (ATRA+As~2~O~3~+IDA vs ATRA+IDA) and maintenance regimen (ATRA+As~2~O~3~ vs ATRA+chemotherapy) on relapse were all analyzed. The risk of relapse in patients administered ATRA+As~2~O~3~ maintenance was significantly lower than that in those administered ATRA+chemotherapy maintenance (*P*=0.004). Other parameters analyzed showed no significant effects on the rate of relapse ([Table 3](#t3-ott-10-2305){ref-type="table"}).

Furthermore, the impacts of sex, age, WBC count at diagnosis, platelet count at diagnosis, hemoglobin level at diagnosis, and types of induction and maintenance regimens on RFS were analyzed. Maintenance with ATRA and As~2~O~3~ was associated with a significantly higher RFS (*P*=0.0159, log-rank; [Table 4](#t4-ott-10-2305){ref-type="table"}). The RFS according to the type of maintenance regimen administered is shown in [Figure 2](#f2-ott-10-2305){ref-type="fig"}. However, no relapse was observed in the ATRA+As~2~O~3~ group, hampering the multivariate analysis to test whether maintenance with ATRA and As~2~O~3~ was an independent factor for RFS.

Due to the relatively high number of patients in our cohort receiving the ATRA+IDA protocol during the induction phase, we further analyzed the impacts of clinicopathologic features on relapse and RFS during maintenance therapy in 47 APL patients receiving ATRA+IDA as the induction regimen. The risk of relapse in the patients who received ATRA+As~2~O~3~ maintenance therapy was significantly lower than that in those who received the ATRA+chemotherapy maintenance (*P*=0.007; [Table 5](#t5-ott-10-2305){ref-type="table"}). In addition, Kaplan--Meier analysis showed that maintenance with ATRA and As~2~O~3~ was associated with a significantly higher RFS (*P*=0.0264, log-rank; [Table 6](#t6-ott-10-2305){ref-type="table"}). Similarly, a multivariate analysis to test whether maintenance with ATRA and As~2~O~3~ was an independent factor for RFS was hampered by the absence of relapse in the ATRA+As~2~O~3~ group. Futhermore, there were too few APL patients (N=11) receiving ATRA+As~2~O~3~+IDA as the induction regimen to make a similar analysis.

Discussion
==========

In the present study, we retrospectively compared the efficacy and toxicity of ATRA plus As~2~O~3~ and classic ATRA plus chemotherapy as maintenance therapy in low- to intermediate-risk APL patients who achieved CR following consolidation therapy. The number of APL patients who received standard induction and consolidation with ATRA and anthracycline-based chemotherapy was 47 (81.0%) and 58 (100%), respectively. The 3-year RFS for patients receiving maintenance therapy with ATRA plus As~2~O~3~ and ATRA plus chemotherapy was 100% and 81.82%, respectively, with a statistically significant difference (*P*=0.0159). These clinical data suggest that maintenance with ATRA and As~2~O~3~ confers a survival benefit in low- to intermediate-risk APL patients achieving CR after effective induction and consolidation with ATRA and anthracycline-based chemotherapy. Our results are consistent with observations from previous studies that report favorable survival attributed to the use of As~2~O~3~ during maintenance.[@b19-ott-10-2305],[@b20-ott-10-2305],[@b23-ott-10-2305] Altogether, these findings show that As~2~O~3~-based maintenance therapy might be another approach to improve the outcome in APL patients achieving CR.

In contrast to ATRA that targets the *RARA* moiety of *PML--RARA*, As~2~O~3~ exerts its therapeutic effects by targeting the *PML* moiety, thereby inducing differentiation and apoptosis of leukemic promyelocytes, as well as the inhibition of leukemic progenitor self-replication and antiangiogenic effects.[@b24-ott-10-2305]--[@b27-ott-10-2305] The synergistic effects between ATRA and As~2~O~3~ have been demonstrated at both the biological[@b28-ott-10-2305],[@b29-ott-10-2305] and clinical levels. For example, recent studies report that the combination of ATRA with As~2~O~3~ administered for initial induction and consolidation therapy improves outcomes compared with standard ATRA plus chemotherapy, particularly in low- to intermediate-risk APL patients.[@b30-ott-10-2305],[@b31-ott-10-2305] Therefore, based on our observations regarding the benefit of maintenance therapy with ATRA and As~2~O~3~, the best timing for the use of As~2~O~3~ in APL, whether during initial remission induction, consolidation, or maintenance, should be further investigated.

In addition to efficacy, safety is another major concern regarding the treatment of low- to intermediate-risk APL patients. In our study, we alternated As~2~O~3~ with conventional chemotherapy. Myelosuppression was observed significantly less frequently in patients administered maintenance therapy with ATRA and As~2~O~3~ than in those administered chemotherapy. The commonly observed adverse effects during maintenance with ATRA and As~2~O~3~ included hepatotoxicity, gastrointestinal reactions, and prolongation of the QT interval, all of which were manageable. Of note, one patient developed hemolysis during maintenance with ATRA plus As~2~O~3~, and the exact reason for this is unknown. Although the drug-induced immune hemolysis was anticipated, a negative direct antiglobulin test result was observed. Another major concern after long-term exposure to inorganic arsenic compounds is the increased risk of secondary tumors.[@b32-ott-10-2305],[@b33-ott-10-2305] No instances of secondary tumors were observed in the present study. In fact, the average total dosage of As~2~O~3~ for maintenance was 26.9 mg/kg in the present study, which is similar to that in the Shanghai trial (28.3 mg/kg).[@b34-ott-10-2305] Thus, APL patients could benefit from As~2~O~3~-based maintenance without overtreatment.

One of the limitations of our study is the retrospective nature; thus, heterogeneity of the data was difficult to be ruled out. Therefore, caution should be taken when interpreting the results of the present study, as they might not be applicable to other populations. Another limitation of the present study is the fact that a greater number of patients received the ATRA plus IDA protocol during the induction phase. Two pilot studies have proven the high efficacy of chemotherapy-free regimens based on As~2~O~3~ in newly diagnosed APL.[@b35-ott-10-2305],[@b36-ott-10-2305] Subsequently, several recent reports provide evidence of the efficacy and safety of ATRA plus As~2~O~3~, with or without a chemotherapy protocol, for first-line therapy in patients with newly diagnosed APL.[@b37-ott-10-2305]--[@b39-ott-10-2305] Furthermore, a recent meta-analysis by Ma et al showed significant benefits of the ATRA plus As~2~O~3~ protocol, compared with the standard ATRA plus chemotherapy protocol, particularly in low- to intermediate-risk APL patients.[@b30-ott-10-2305] In line with results of these pilot studies, the final results of the randomized Italian-German APL0406 trial demonstrated the advantages of ATRA plus As~2~O~3~ over ATRA plus chemotherapy for induction and consolidation therapy in low- to intermediate-risk APL.[@b31-ott-10-2305] These data suggest that the standard first-line treatment for newly diagnosed APL is now shifting towards induction and consolidation regimens that include ATRA and arsenic. Thus, the variables associated with frontline induction and consolidation therapies in the present study might work against future outcomes. For example, a recent randomized non-inferiority study demonstrated that DFS was not significantly different among low- to intermediate-risk APL patients who were reaching molecular CR after consolidation therapy including As~2~O~3~ and received ATRA+chemotherapy maintenance therapy vs those who received no maintenance therapy, and suggested that maintenance therapy may not be needed if patients are treated with an intensive post-remission regimen including As~2~O~3~.[@b40-ott-10-2305] The question of whether maintenance with ATRA and As~2~O~3~ benefits low- to intermediate-risk APL patients in whom As~2~O~3~ has been incorporated in induction and consolidation will need to be addressed in future studies.

In conclusion, the present study, conducted in a well-defined cohort, albeit a retrospective single-center analysis of a relatively small number of subjects, showed that maintenance therapy with ATRA and As~2~O~3~ was beneficial for low- to intermediate-risk APL patients who were effectively treated to achieve CR. In addition, the use of As~2~O~3~ in maintenance precluded the need for myelosuppressive chemotherapy. However, further clinical trials with reliable designs are needed to confirm the results of the present study.
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###### 

Clinicopathologic characteristics of 58 patients with APL receiving different maintenance regimens

  Characteristic                             ATRA+As~2~O~3~ maintenance (N=30)   ATRA+chemotherapy maintenance (N=28)   *P*-value
  ------------------------------------------ ----------------------------------- -------------------------------------- -----------
  Age (years), median (range)                41 (15--64)                         43.5 (17--70)                          0.4933
   15--39, n (%)                             12 (40.0)                           12 (42.9)                              0.557
   40--60, n (%)                             16 (53.3)                           12 (42.9)                              
   \>60, n (%)                               2 (6.7)                             4 (14.2)                               
  Sex                                                                                                                   
   Male, n (%)                               12 (40.0)                           19 (67.9)                              0.034
   Female, n (%)                             18 (60.0)                           9 (32.1)                               
  WBC count (×10^9^/L), median (range)       1.49 (0.52--6.83)                   2.14 (0.85--8.7)                       0.0165
   \<5, n (%)                                28 (93.3)                           20 (71.4)                              0.027
   5--10, n (%)                              2 (6.7)                             8 (28.6)                               
  Platelet count, ×10^9^/L, median (range)   20.5 (2--176)                       28.5 (3--135)                          0.4884
   ≤40, n (%)                                24 (80.0)                           17 (60.7)                              0.107
   \>40, n (%)                               6 (20.0)                            11 (39.3)                              
  Hemoglobin (g/L), median (range)           81 (39--144)                        90.5 (44--149)                         0.1435
  Induction regimens                                                                                                    
   ATRA+As~2~O~3~+IDA, n (%)                 8 (26.7)                            3 (10.7)                               0.121
   ATRA+IDA, n (%)                           22 (73.3)                           25 (89.3)                              

**Abbreviations:** APL, acute promyelocytic leukemia; As~2~O~3~, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.

###### 

Adverse events during maintenance therapy

  Adverse events               ATRA+As~2~O~3~ maintenance (N=30)   ATRA+chemotherapy maintenance (N=28)   *P*-value
  ---------------------------- ----------------------------------- -------------------------------------- -----------
  Neutropenia (grade 3--4)     0                                   9                                      0.001
  Liver function derangement   3                                   4                                      0.701
  QT prolongation              2                                   0                                      0.492
  Dyspepsia                    1                                   3                                      0.344
  Herpes zoster reactivation   0                                   1                                      0.483
  Hemolysis                    1                                   0                                      1.000

**Abbreviations:** ATRA, all-trans retinoic acid; As~2~O~3~, arsenic trioxide.

###### 

Impacts of clinicopathologic features on relapse in 58 APL patients during maintenance therapy

  Clinicopathologic parameters   Outcome   *P*-value   
  ------------------------------ --------- ----------- -------
  Sex                                                  0.432
   Male                          26        5           
   Female                        25        2           
  Age (years)                                          1.000
   ≤40                           25        3           
   \>40                          26        4           
  WBC count (×10^9^/L)                                 0.592
   ≤5                            43        5           
   \>5                           8         2           
  Platelet count (×10^9^/L)                            0.661
   ≤40                           35        6           
   \>40                          16        1           
  Hemoglobin (g/L)                                     0.083
   \<100                         39        3           
   ≥100                          12        4           
  Induction regimens                                   0.327
   ATRA+As~2~O~3~+IDA            11        0           
   ATRA+IDA                      40        7           
  Maintenance regimens                                 0.004
   ATRA+As~2~O~3~                30        0           
   ATRA+chemotherapy             21        7           

**Abbreviations:** APL, acute promyelocytic leukemia; As~2~O~3~, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.

###### 

Impacts of clinicopathologic parameters on RFS in 58 APL patients during maintenance therapy

  Clinicopathologic parameters   3-year RFS   *P*-value (log-rank)
  ------------------------------ ------------ ----------------------
  Sex                                         0.4376
   Male                          0.8640       
   Female                        0.9630       
  Age (years)                                 0.8146
   ≤40                           0.8889       
   \>40                          0.9305       
  WBC count (×10^9^/L)                        0.6536
   ≤5                            0.9128       
   \>5                           0.9000       
  Platelet count (×10^9^/L)                   0.3020
   ≤40                           0.8733       
   \>40                          1.0000       
  Hemoglobin (g/L)                            0.0895
   \<100                         0.9491       
   ≥100                          0.8125       
  Induction regimens                          0.2724
   ATRA+As~2~O~3~+IDA            1.0000       
   ATRA+IDA                      0.8908       
  Maintenance regimens                        0.0159
   ATRA+As~2~O~3~                1.0000       
   ATRA+chemotherapy             0.8182       

**Abbreviations:** APL, acute promyelocytic leukemia; As~2~O~3~, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; RFS, relapse-free survival; WBC, white blood cell.

###### 

Impacts of clinicopathologic features on relapse during maintenance therapy in 47 APL patients receiving ATRA+IDA as an induction regimen

  Clinicopathologic parameters   Outcome   *P*-value   
  ------------------------------ --------- ----------- -------
  Sex                                                  0.295
   Male                          20        5           
   Female                        20        2           
  Age (years)                                          0.727
   ≤40                           20        3           
   \>40                          20        4           
  WBC count (×10^9^/L)                                 0.492
   ≤5                            33        5           
   \>5                           7         2           
  Platelet count (×10^9^/L)                            0.331
   ≤40                           27        6           
   \>40                          13        1           
  Hemoglobin (g/L)                                     0.086
   \<100                         30        3           
   ≥100                          10        4           
  Maintenance regimens                                 0.007
   ATRA+As~2~O~3~                22        0           
   ATRA+chemotherapy             18        7           

**Abbreviations:** APL, acute promyelocytic leukemia; As~2~O~3~, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; WBC, white blood cell.

###### 

Impacts of clinicopathologic parameters on RFS during maintenance therapy in 47 APL patients receiving ATRA+IDA as an induction regimen

  Clinicopathologic parameters   3-year RFS   *P*-value (log-rank)
  ------------------------------ ------------ ----------------------
  Sex                                         0.4381
   Male                          0.8337       
   Female                        0.9545       
  Age (years)                                 0.7301
   ≤40                           0.8696       
   \>40                          0.9079       
  WBC count (×10^9^/L)                        0.7274
   ≤5                            0.8904       
   \>5                           0.8889       
  Platelet count (×10^9^/L)                   0.2928
   ≤40                           0.8436       
   \>40                          1.0000       
  Hemoglobin (g/L)                            0.1158
   \<100                         0.9351       
   ≥100                          0.7857       
  Maintenance regimens                        0.0264
   ATRA+As~2~O~3~                1.0000       
   ATRA+chemotherapy             0.7958       

**Abbreviations:** APL, acute promyelocytic leukemia; As~2~O~3~, arsenic trioxide; ATRA, all-trans retinoic acid; IDA, idarubicin; RFS, relapse-free survival; WBC, white blood cell.
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